Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Assets: 2022-2025

Historic Assets for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Sep 2025 value amounting to $104.8 million.

  • Orchestra BioMed Holdings' Assets rose 39.15% to $104.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.8 million, marking a year-over-year increase of 39.15%. This contributed to the annual value of $76.2 million for FY2024, which is 20.00% down from last year.
  • Latest data reveals that Orchestra BioMed Holdings reported Assets of $104.8 million as of Q3 2025, which was up 144.73% from $42.8 million recorded in Q2 2025.
  • Orchestra BioMed Holdings' Assets' 5-year high stood at $161.6 million during Q2 2022, with a 5-year trough of $42.8 million in Q2 2025.
  • In the last 3 years, Orchestra BioMed Holdings' Assets had a median value of $82.6 million in 2024 and averaged $89.7 million.
  • As far as peak fluctuations go, Orchestra BioMed Holdings' Assets skyrocketed by 69.50% in 2023, and later tumbled by 42.50% in 2024.
  • Over the past 4 years, Orchestra BioMed Holdings' Assets (Quarterly) stood at $95.6 million in 2022, then declined by 0.38% to $95.2 million in 2023, then declined by 20.00% to $76.2 million in 2024, then surged by 39.15% to $104.8 million in 2025.
  • Its Assets stands at $104.8 million for Q3 2025, versus $42.8 million for Q2 2025 and $59.1 million for Q1 2025.